What is
?
Fast Acting: In log reduction studies, exposure to IrriSept solution at one minute interval resulted in 99.999% reduction for MRSA and 99.9999% reduction for Pseudomonas aeroginosa1.
Persistent: In laboratory testing, IrriSept continues to destroy and inhibit MRSA and coagulase-negative Staphylococcus aureus for up to 14 days2.
Safe: IrriSept has passed FDA-required testing for cytotoxicity, skin irritation and immune allergic response3.
Unique Delivery System: Patented irrigation system engineered to meet recommended PSI range, to optimize cleansing and debridement.
use include:
-
Surgical Procedures (as a final rinse before closure)
- Orthopedic Surgery
- General Surgery
- Plastic & Reconstructive Surgery
- Cardiothoracic Surgery
- Neurologic Surgery
-
Surgical Site Infections (SSI)
Skin & Soft Tissue Infections (SSTI)
Abscesses
Lacerations
Deep Traumatic Wounds
Delayed Closure
Wound Dehiscence
Pilonidal Cysts
Burns
- Edmiston et al 2012, Surgical Microbiology Research Laboratory, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin
- Laboratory Testing Records, "Chlorhexidine Gluconate (CHG) Bacterial Study Report," on file at IrriMax Corporation.
- Biocompatibility compliance tests completed per FDA's Blue Book Memorandum G95-1 and ISO 10993-1, Biological Evaluation of Medical Devices, on file at IRRIMAX Corporation

